Litcius/Paper detail

Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium

Imke Anne Maartje Ditters, Hidde Harmen Huidekoper, Michelle Elisabeth Kruijshaar, Dimitris Rizopoulos, Andreas Hahn, Tiziana Enrica Mongini, François Labarthe, Marine Tardieu, Brigitte Chabrol, Anais Brassier, Rossella Parini, Giancarlo Parenti, Nadine Anna Maria Elisabeth van der Beek, Ans Tjitske van der Ploeg, Johanna Maria Pieternel van den Hout, Eugen Mengel, Julia Hennermann, Martin Smitka, Nicole Muschol, Thorsten Marquardt, Martina Marquardt, Charlotte Thiels, Marco Spada, Veronica Pagliardini, Francesca Menni, Roberto della Casa, Federica Deodato, Serena Gasperini, Alberto Burlina, Alice Donati, Samia Pichard, François Feillet, Fréderic Huet, Karine Mention, Didier Eyer, Alice Kuster, Caroline Espil Taris, Jérémie Lefranc, Magalie Barth, Henri Bruel, Laurent Chevret, Gaele Pitelet, Catherine Pitelet, François Rivier, Dries Dobbelaere

2021The Lancet Child & Adolescent Health66 citationsDOI

Topics & Concepts

MedicineObservational studyCohort studyPediatricsCohortPhysical therapyMEDLINERetrospective cohort studyMulticenter studyProspective cohort studySurvival analysisLysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusGlycosylation and Glycoproteins Research
Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium | Litcius